Literature DB >> 11483625

Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.

H Campos1, D Perlov, C Khoo, F M Sacks.   

Abstract

Apolipoprotein (apo) E and apoC-III concentrations in VLDL and LDL are associated with coronary heart disease. We studied the relationship between apoE and apoC-III and the abnormal concentrations and distribution of apoB lipoproteins in 10 hypercholesterolemic and 13 hypertriglyceridemic patients compared with 12 normolipidemic subjects (mean age, 45 years). Sixteen distinct types of apoB lipoprotein particles were separated by first using anti-apoE and anti-apoC-III immunoaffinity chromatography in sequence and then ultracentrifugation [light VLDL, dense VLDL, IDL, and LDL, with apoE with or without apoC-III (E(+)C-III(+), E(+)C-III(-)) or without apoE with or without apoC-III (E(-)C-III(+), E(-)C-III(-))]. The concentrations of VLDL particles with apoC-III (E(+)C-III(+), E(-)C-III(+)) were increased in the hypertriglyceridemic group compared with the hypercholesterolemic and normolipidemic groups. These particles were the most triglyceride rich of the particle types, and their triglyceride content was twice as high in hypertriglyceridemics compared with the other two groups. Hypertriglyceridemics had a similar concentration of total E(-)C-III(-) particles compared with normolipidemics, but the E(-)C-III(-) particles were distributed more to VLDL and IDL than to LDL. Hypercholesterolemics, in contrast, were distinguished from the normolipidemic group by 2-fold higher concentrations of apoB lipoproteins without apoE or apoC-III (E(-)C-III(-)), mainly LDL, which had high cholesterol content. Nonetheless, both normolipidemics and hypercholesterolemics had apoC-III-containing VLDL, which comprised 68% and 43% of their total VLDL particles. E(+)C-III(-) particles were a minor type, comprising <10% of particles in all lipoproteins and patient groups. Therefore, VLDL particles with apoC-III may play a central role in identifying the high risk of coronary heart disease in hypertriglyceridemia, but their substantial prevalence in normolipidemics may be of clinical significance as well.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483625

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  26 in total

1.  Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans.

Authors:  Chunyu Zheng; Susan J Murdoch; John D Brunzell; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-01-12       Impact factor: 8.311

2.  Aggregated electronegative low density lipoprotein in human plasma shows a high tendency toward phospholipolysis and particle fusion.

Authors:  Cristina Bancells; Sandra Villegas; Francisco J Blanco; Sonia Benítez; Isaac Gállego; Lorea Beloki; Montserrat Pérez-Cuellar; Jordi Ordóñez-Llanos; José Luis Sánchez-Quesada
Journal:  J Biol Chem       Date:  2010-07-29       Impact factor: 5.157

Review 3.  Role of triglyceride-rich lipoproteins in diabetic nephropathy.

Authors:  John C Rutledge; Kit F Ng; Hnin H Aung; Dennis W Wilson
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

4.  Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease.

Authors:  Carlos O Mendivil; Eric B Rimm; Jeremy Furtado; Stephanie E Chiuve; Frank M Sacks
Journal:  Circulation       Date:  2011-10-10       Impact factor: 29.690

5.  Associations of anthropometry and lifestyle factors with HDL subspecies according to apolipoprotein C-III.

Authors:  Manja Koch; Jeremy D Furtado; Gordon Z Jiang; Brianna E Gray; Tianxi Cai; Frank Sacks; Anne Tjønneland; Kim Overvad; Majken K Jensen
Journal:  J Lipid Res       Date:  2017-04-01       Impact factor: 5.922

Review 6.  The role of non-LDL:non-HDL particles in atherosclerosis.

Authors:  Jere P Segrest
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

7.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

8.  Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease.

Authors:  Beatriz Talayero; Liyun Wang; Jeremy Furtado; Vincent J Carey; George A Bray; Frank M Sacks
Journal:  J Lipid Res       Date:  2014-06-25       Impact factor: 5.922

Review 9.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

10.  ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Authors:  Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.